Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ConvaTec ( (GB:CTEC) ) has issued an announcement.
ConvaTec Group PLC has executed a share buyback transaction, purchasing 1,809,168 ordinary shares as part of its $300 million buyback program announced in August 2025. The shares were acquired at prices ranging from 233.80 to 238.20 pence and will be held in treasury, impacting the company’s total voting rights and potentially influencing shareholder interests.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £266.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
Spark’s Take on GB:CTEC Stock
According to Spark, TipRanks’ AI Analyst, GB:CTEC is a Outperform.
ConvaTec’s strong financial performance, characterized by solid revenue growth and profitability, is the most significant factor driving its stock score. Technical analysis indicates moderate bullish momentum, though tempered by some bearish signals. The valuation suggests the stock might be overvalued, but the dividend yield offers some compensation. Overall, ConvaTec is well-positioned in its industry, though investors should be mindful of valuation concerns.
To see Spark’s full report on GB:CTEC stock, click here.
More about ConvaTec
ConvaTec Group PLC operates in the medical products and technologies industry, focusing on providing solutions for advanced wound care, ostomy care, continence and critical care, and infusion care. The company serves healthcare providers and patients worldwide, aiming to enhance the quality of life for individuals with chronic conditions.
Average Trading Volume: 7,931,154
Technical Sentiment Signal: Buy
Current Market Cap: £4.68B
For an in-depth examination of CTEC stock, go to TipRanks’ Overview page.